First lab worldwide to offer URO17™; an innovative new bladder cancer test that has demonstrated 95%+ sensitivity and 90%+ specificity in published studies. Recognized by the FDA in Nov '19 as a "Breakthrough", URO17™ is currently being utilized by customers nationwide due to the significant clinical and financial benefits.LUGPA POL's, commercial labs, hospital based pathology practices, GYN, Internal Medicine, and primary care practices are active clients.Fresh off a record 2019 for both specimen volume and revenue, Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Hematology / Oncology, GYN, Breast, ENT, Podiatry, etc. Acupath offers an extensive test menu on both a global and TC/PC basis, processes well over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing for the detection of bladder cancer (UroVysion™), prostate cancer (PTEN ERG), and esophageal cancer (Barrett’s esophagus FISH).

KDx is the developer of URO17, an innovative bladder cancer biomarker that significantly improves on the traditional tests and methodology of evaluating patients at risk for bladder cancer. I can help you incorporate URO17 into your practice / POL to leverage the significant clinical and financial benefits.

P4 Diagnostics is a leading sub-specialized anatomic pathology laboratory with a specific expertise in helping clients offer the best available patient care, while operating their practices most efficiently and profitably. As a strategic partner of VitalAxis, P4 offers best-in-class IT solutions, innovative molecular testing, and advanced business development solutions.

Describe your position

Sold anatomic pathology services for DIANON Systems. Earned multiple President's Club awards and was consistently a top ranked sales person.